Taysha Gene Therapies (TSHA) Reiterated at Overweight by Cantor Fitzgerald on Phase 1/2 Data
Tweet Send to a Friend
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $19.00 price target on Taysha Gene Therapies (NASDAQ: TSHA).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
